Abstract

National Cancer Center Japan has initiated ATLAS (Asian Clinical Trials Network for Cancers) project since 2020 with financial support from AMED that is a Japanese public funding agency. The goals of ATLAS are to strengthen multilateral cooperation with ATLAS member institutions and improve the cancer clinical research capabilities; establish robust infrastructure for conducting oncology trials with high quality clinical data; deliver novel drugs and practice changing research results to cancer patients. To achieve this goal, construction of well-organized governance as a cooperative group such as EORTC, SWOG, or JCOG is urgently needed. We have just started to prepare the establishment of the ATLAS Board that is the guardian of ATLAS’s sustainability.